Viewing Study NCT03021304


Ignite Creation Date: 2025-12-24 @ 8:03 PM
Ignite Modification Date: 2026-01-05 @ 6:32 PM
Study NCT ID: NCT03021304
Status: COMPLETED
Last Update Posted: 2019-07-23
First Post: 2017-01-12
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Study of Mepolizumab Safety Syringe in Asthmatics
Sponsor: GlaxoSmithKline
Organization:

Study Overview

Official Title: An Open-label, Single Arm, Repeat Dose, Multi-centre Study to Evaluate the Use of a Safety Syringe for the Subcutaneous Administration of Mepolizumab in Subjects With Severe Eosinophilic Asthma (Study 205667)
Status: COMPLETED
Status Verified Date: 2019-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: True
If Expanded Access, NCT#: NCT00244686
Has Expanded Access, NCT# Status: NO_LONGER_AVAILABLE
Acronym: None
Brief Summary: This study is aimed to assess the correct real-world use of a safety syringe for the repeat self-administration of mepolizumab SC. This Phase III study will be an open-label, single-arm, repeat-dose, multi-centre study of mepolizumab liquid drug product in a safety syringe (100 milligrams \[mg\]) administered subcutaneously (SC) every 4 weeks (3 doses) in subjects with severe eosinophilic asthma. Subjects will receive 100 mg mepolizumab SC as a single injection that is self-administered in the thigh, abdomen or administered in the upper arm (caregiver only). Each subject will participate in the study for up to 18 weeks including pre-screening visit, a screening visit and a 12-week treatment period which concludes with end of study assessments (Visit 5) 4 weeks after the last dose of mepolizumab. Approximately 55 Subjects will be enrolled in the study.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2016-001831-10 EUDRACT_NUMBER None View